Literature DB >> 1600352

Hemodynamic effects of amiodarone during acute and chronic treatment in patients with recurrent sustained ventricular tachycardia.

M Manz1, W Jung, B Lüderitz.   

Abstract

In 15 patients with recurrent ventricular tachycardia, the hemodynamic effects of amiodarone were evaluated under oral loading (1000 mg/day for 14-16 days) and during chronic treatment (600 mg/day for a further 10 weeks). In all patients, coronary artery disease was present with a mean ejection fraction of 37%+/- 10%. The cardiac output during the sinus rhythm, as determined by thermodilution, did not change significantly during loading with amiodarone. During ventricular tachycardia, the cardiac output increased from 3.7 +/- 1.3 to 4.5 +/- 1.6 1/min under the influence of amiodarone in 5 patients. Echocardiographic measurements of the left ventricle dimensions did not show a directed change of the enddiastolic and endsystolic diameters and the fraction shortening at the end of the loading period and after 3 months of maintenance therapy. No negative inotropic effect of amiodarone could be demonstrated in patients with recurrent ventricular tachycardia and impaired left ventricular function due to coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1600352     DOI: 10.1007/bf00235524

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  19 in total

1.  Congestive heart failure caused by oral disopyramide.

Authors:  P J Podrid; A Schoeneberger; B Lown
Journal:  N Engl J Med       Date:  1980-03-13       Impact factor: 91.245

2.  Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary haemodynamics and on cardiac intracellular potentials.

Authors:  B N Singh; D E Jewitt; J M Downey; E S Kirk; E H Sonnenblick
Journal:  Clin Exp Pharmacol Physiol       Date:  1976 Sep-Oct       Impact factor: 2.557

3.  Determinants of survival in patients with ventricular tachyarrhythmias.

Authors:  C D Swerdlow; R A Winkle; J W Mason
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

4.  The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction.

Authors:  J T Bigger; J L Fleiss; R Kleiger; J P Miller; L M Rolnitzky
Journal:  Circulation       Date:  1984-02       Impact factor: 29.690

5.  Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors.

Authors:  R Charlier
Journal:  Br J Pharmacol       Date:  1970-08       Impact factor: 8.739

6.  Amiodarone in refractory life-threatening ventricular arrhythmias.

Authors:  K Nademanee; B N Singh; J Hendrickson; V Intarachot; B Lopez; G Feld; D S Cannom; J L Weiss
Journal:  Ann Intern Med       Date:  1983-05       Impact factor: 25.391

7.  Risk factors for sudden death after acute myocardial infarction: two-year follow-up.

Authors:  J Mukharji; R E Rude; W K Poole; N Gustafson; L J Thomas; H W Strauss; A S Jaffe; J E Muller; R Roberts; D S Raabe
Journal:  Am J Cardiol       Date:  1984-07-01       Impact factor: 2.778

8.  Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

Authors:  J J Heger; E N Prystowsky; W M Jackman; G V Naccarelli; K A Warfel; R L Rinkenberger; D P Zipes
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

9.  Rapid suppression of complex ventricular arrhythmias with high-dose oral amiodarone.

Authors:  N D Mostow; T R Vrobel; D Noon; L Rakita
Journal:  Circulation       Date:  1986-06       Impact factor: 29.690

10.  Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease.

Authors:  L N Horowitz; A M Greenspan; S R Spielman; C R Webb; J Morganroth; H Rotmensch; N M Sokoloff; A P Rae; B L Segal; H R Kay
Journal:  Am J Cardiol       Date:  1985-02-01       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.